Company Focus
Biogen
Latest Biogen News
Biotechnology
US biotech Biogen has received US Food and Drug Administration (FDA) Breakthrough Therapy designation for salanersen, its investigational antisense oligonucleotide for spinal muscular atrophy (SMA). 5 June 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Latest News & Features of interest to Biogen
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
US biotech Biogen has received US Food and Drug Administration (FDA) Breakthrough Therapy designation for salanersen, its investigational antisense oligonucleotide for spinal muscular atrophy (SMA). 5 June 2026
Pharmaceutical
A feature on the amyloidosis space. 4 June 2026
Biotechnology
Australian clinical-stage biotech Neurizon Therapeutics is expanding the NUZ-001 arm of the HEALEY ALS Platform Trial after recruitment ran faster than expected. 4 June 2026
Pharmaceutical
Shares of US biopharma company Cingulate closed up 11.9% at $4.03 on Tuesday, after it announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter for its New Drug Application (NDA) for CTx-1301 (dexmethylphenidate HCl) for the treatment of attention deficit/hyperactivity disorder (ADHD). 4 June 2026
Biotechnology
Belgian biopharma UCB and US biotech Biogen have reported further Phase III data for dapirolizumab pegol in systemic lupus erythematosus, as they try to carve out a place in a more active lupus market. 4 June 2026
Biotechnology
Danish CNS specialist Lundbeck (and Cradle, a Dutch AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. 3 June 2026
Pharmaceutical
Colorado, USA-based Edgewise Therapeutics, a muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement with French independent pharma company Servier. 2 June 2026
Pharmaceutical
German neurology specialist Merz Therapeutics has signed an exclusive licensing and collaboration agreement with Jiangxi Kvvit Pharmaceutical covering Inbrija (levodopa) in mainland China, Hong Kong and Macao, as the privately held company pushes deeper into Asian neurology markets. 2 June 2026
Pharmaceutical
Cambridge, USA-based drug developer Agios Pharmaceuticals has announced an agreement with Oscotec, a clinical-stage drug discovery and development company focused on immunology and oncology, headquartered in South Korea, to license the exclusive global rights to cevidoplenib, a novel, next-generation, oral spleen tyrosine kinase (SYK) inhibitor. 2 June 2026
Latest In Brief for Biogen
Pharmaceutical
A consortium led by CVC Capital Partners has launched a 10.9 billion euros ($12.65 billion) bid to take Italian drugmaker Recordati (RECI: MI) private, in a deal that would tighten the buyout specialist’s control of the company and extend its bet on the rare disease market. 23 May 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze